Correlation Between Golden Biotechnology and GeneReach Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Golden Biotechnology and GeneReach Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Golden Biotechnology and GeneReach Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Golden Biotechnology and GeneReach Biotechnology, you can compare the effects of market volatilities on Golden Biotechnology and GeneReach Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Golden Biotechnology with a short position of GeneReach Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Golden Biotechnology and GeneReach Biotechnology.

Diversification Opportunities for Golden Biotechnology and GeneReach Biotechnology

0.85
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Golden and GeneReach is 0.85. Overlapping area represents the amount of risk that can be diversified away by holding Golden Biotechnology and GeneReach Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GeneReach Biotechnology and Golden Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Golden Biotechnology are associated (or correlated) with GeneReach Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GeneReach Biotechnology has no effect on the direction of Golden Biotechnology i.e., Golden Biotechnology and GeneReach Biotechnology go up and down completely randomly.

Pair Corralation between Golden Biotechnology and GeneReach Biotechnology

Assuming the 90 days trading horizon Golden Biotechnology is expected to under-perform the GeneReach Biotechnology. In addition to that, Golden Biotechnology is 1.77 times more volatile than GeneReach Biotechnology. It trades about -0.11 of its total potential returns per unit of risk. GeneReach Biotechnology is currently generating about -0.08 per unit of volatility. If you would invest  3,875  in GeneReach Biotechnology on September 20, 2024 and sell it today you would lose (1,205) from holding GeneReach Biotechnology or give up 31.1% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Golden Biotechnology  vs.  GeneReach Biotechnology

 Performance 
       Timeline  
Golden Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Golden Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
GeneReach Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days GeneReach Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Golden Biotechnology and GeneReach Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Golden Biotechnology and GeneReach Biotechnology

The main advantage of trading using opposite Golden Biotechnology and GeneReach Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Golden Biotechnology position performs unexpectedly, GeneReach Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneReach Biotechnology will offset losses from the drop in GeneReach Biotechnology's long position.
The idea behind Golden Biotechnology and GeneReach Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Complementary Tools

Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Valuation
Check real value of public entities based on technical and fundamental data
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios